Obodence is a medicine used to treat the following conditions: - osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and in men who have an increased risk of fractures (broken bones). In women who have been through the menopause, Obodence reduces the risk of fractures in the spine and elsewhere in the body, including the hips; - bone loss in men receiving treatment for prostate cancer that increases their risk of fractures. Obodence reduces the risk of fractures in the spine; - bone loss in adults at increased risk of fractures due to long term treatment with corticosteroid medicines given by mouth or injection. Obodence is a biological medicines and contains the active substance denosumab. It is a ‘biosimilar medicine’; this means that Obodence is highly similar to another biological medicine (the ‘reference medicine’) that is already authorised in the EU. The reference medicine for Obodence is Prolia.
Therapeutic Indication
### Therapeutic indication Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women denosumab significantly reduces the risk of vertebral, non-vertebral and hip fractures. Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures (see section 5.1). In men with prostate cancer receiving hormone ablation, denosumab significantly reduces the risk of vertebral fractures. Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture (see section 5.1).
Therapeutic Area (MeSH)
ATC Code
M05BX04
ATC Item
denosumab
Pharmacotherapeutic Group
Drugs for treatment of bone diseases
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| denosumab | N/A | 地舒单抗 |
EMA Name
Obodence
Medicine Name
Obodence
Aliases
N/ANo risk management plan link.
